- 614, G80, E60, B01 -

Sickle Cell Disease Association of America SCDAA OSCHA Sickle Cell Disease Association of America SCDAA OSCHA September is National Sickle Cell Month September is National Sickle Cell Month FDA Approves New Treatment for Sickle Cell Disease For Immediate Release December 08 2023 Today the U. S. Food and Drug Administration approved two milestone treatments Casgevy and Lyfgenia representing the first cellbased gene therapies for the treatment of sickle cell disease SCD in patients 12 years and older. Additionally one of these therapies Casgevy is the first FDAapproved treatment to utilize a type of novel genome editing technology signaling an innovative advancement in the field of gene therapy.